Marimed (MRMD) EBIT (2011 - 2026)

Marimed (MRMD) has 16 years of EBIT data on file, last reported at $125000.0 in Q1 2026.

• EBIT for Q1 2026 came in at $125000.0, up 113.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.7 million (down 2055.84% YoY), and the FY2025 annual result was -$2.8 million, down 208.09% from the prior year.
• EBIT improved to $125000.0 in Q1 2026 per MRMD's latest filing, from -$4.5 million in the prior quarter.
• Over five years, EBIT peaked at $7.0 million in Q1 2022 and troughed at -$4.5 million in Q4 2025.
• A 5-year average of $2.1 million and a median of $2.0 million in 2024 frame the typical range for EBIT.
• The sharpest annual moves came in 2022 and 2025: EBIT surged 156.77% in 2022, then slumped 208.24% in 2025.
• A 5-year view of EBIT shows it stood at $3.1 million in 2022, then declined by 21.95% to $2.4 million in 2023, then slumped by 160.89% to -$1.5 million in 2024, then tumbled by 208.24% to -$4.5 million in 2025, then jumped by 102.76% to $125000.0 in 2026.
• Business Quant data shows MRMD's EBIT at $125000.0 in Q1 2026, -$4.5 million in Q4 2025, and $1.6 million in Q3 2025.